论文部分内容阅读
目的:评价a硫辛酸联合前列地尔治疗糖尿病早期肾病(DN)及视网膜病变(DR)的疗效。方法:选择我院糖尿病早期肾病及视网膜病变患者100例,随机分为治疗组50例。治疗组静脉点滴前列地尔(凯时)10微克加入0.9%氯化钠100毫升,每日一次,硫辛酸0.3克加入0.9%氯化钠250毫升,连续3周。对照组静脉点滴前列地尔(凯时)10微克加入0.9%氯化钠100毫升,每日一次,但控制血脂/血糖等其他方法两组相似。观察两组患者治疗前后尿微量白蛋白及眼底照相的变化。结果:经前列地尔联合硫辛酸治疗后患者尿微量白蛋白明显下降,眼底照相明显改善,与治疗相比有显著性差异(P<0.05)。结论:前列地尔联合硫辛酸是早期糖尿病肾病安全,有效地治疗方法,早期应用有利于延缓糖尿病早期微血管病变的进展。
Objective: To evaluate the efficacy of a lipoic acid combined with alprostadil in the treatment of diabetic nephropathy (DN) and retinopathy (DR). Methods: 100 cases of diabetic nephropathy and retinopathy in our hospital were randomly divided into treatment group (50 cases). The treatment group intravenous alprostadil (Kay hours) 10 micrograms added 0.9% sodium chloride 100 ml once daily, 0.3 g lipoic acid was added 0.9% sodium chloride 250 ml for 3 weeks. The control group intravenous alprostadil (Kai) 10 micrograms added 0.9% sodium chloride 100 ml once daily, but other methods of control of blood lipids / blood glucose and other groups were similar. The changes of urinary albumin and fundus photography before and after treatment were observed in both groups. Results: Urine microalbumin decreased significantly after the administration of lipoic acid, and the fundus photography was significantly improved, which was significantly different from the treatment (P <0.05). Conclusions: Alprostadil combined with lipoic acid is a safe and effective treatment for early diabetic nephropathy. Early application of alprostadil is beneficial to delay the progression of early diabetic microangiopathy.